OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Paroxysmal nocturnal hemoglobinuria and eculizumab
Lucio Luzzatto, Antonio M. Risitano, Rosario Notaro
Haematologica (2010) Vol. 95, Iss. 4, pp. 523-526
Open Access | Times Cited: 65
Lucio Luzzatto, Antonio M. Risitano, Rosario Notaro
Haematologica (2010) Vol. 95, Iss. 4, pp. 523-526
Open Access | Times Cited: 65
Showing 1-25 of 65 citing articles:
Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria
Antonio M. Risitano, Daniel Ricklin, Yijun Huang, et al.
Blood (2014) Vol. 123, Iss. 13, pp. 2094-2101
Open Access | Times Cited: 187
Antonio M. Risitano, Daniel Ricklin, Yijun Huang, et al.
Blood (2014) Vol. 123, Iss. 13, pp. 2094-2101
Open Access | Times Cited: 187
Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT
Antonio M. Risitano, Serena Marotta, Patrizia Ricci, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 172
Antonio M. Risitano, Serena Marotta, Patrizia Ricci, et al.
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 172
A guide to complement biology, pathology and therapeutic opportunity
Dimitrios C. Mastellos, George Hajishengallis, John D. Lambris
Nature reviews. Immunology (2023) Vol. 24, Iss. 2, pp. 118-141
Closed Access | Times Cited: 104
Dimitrios C. Mastellos, George Hajishengallis, John D. Lambris
Nature reviews. Immunology (2023) Vol. 24, Iss. 2, pp. 118-141
Closed Access | Times Cited: 104
Paroxysmal Nocturnal Hemoglobinuria
Bruno Rotoli, Khédoudja Nafa, Antonio M. Risitano
Humana Press eBooks (2007), pp. 838-847
Closed Access | Times Cited: 167
Bruno Rotoli, Khédoudja Nafa, Antonio M. Risitano
Humana Press eBooks (2007), pp. 838-847
Closed Access | Times Cited: 167
Rational Engineering of a Minimized Immune Inhibitor with Unique Triple-Targeting Properties
Christoph Q. Schmidt, Hongjun Bai, Zhuoer Lin, et al.
The Journal of Immunology (2013) Vol. 190, Iss. 11, pp. 5712-5721
Open Access | Times Cited: 127
Christoph Q. Schmidt, Hongjun Bai, Zhuoer Lin, et al.
The Journal of Immunology (2013) Vol. 190, Iss. 11, pp. 5712-5721
Open Access | Times Cited: 127
The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment opsonization
Antonio M. Risitano, Rosario Notaro, Caterina Pascariello, et al.
Blood (2012) Vol. 119, Iss. 26, pp. 6307-6316
Open Access | Times Cited: 120
Antonio M. Risitano, Rosario Notaro, Caterina Pascariello, et al.
Blood (2012) Vol. 119, Iss. 26, pp. 6307-6316
Open Access | Times Cited: 120
Progress and Trends in Complement Therapeutics
Daniel Ricklin, John D. Lambris
Advances in experimental medicine and biology (2012), pp. 1-22
Open Access | Times Cited: 111
Daniel Ricklin, John D. Lambris
Advances in experimental medicine and biology (2012), pp. 1-22
Open Access | Times Cited: 111
Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria
Antonio M. Risitano, Austin Kulasekararaj, Jong Wook Lee, et al.
Haematologica (2020) Vol. 106, Iss. 12, pp. 3188-3197
Open Access | Times Cited: 80
Antonio M. Risitano, Austin Kulasekararaj, Jong Wook Lee, et al.
Haematologica (2020) Vol. 106, Iss. 12, pp. 3188-3197
Open Access | Times Cited: 80
Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab
Austin Kulasekararaj, Antonio M. Risitano, Jaroslaw P. Maciejewski, et al.
Blood (2021) Vol. 138, Iss. 20, pp. 1928-1938
Open Access | Times Cited: 67
Austin Kulasekararaj, Antonio M. Risitano, Jaroslaw P. Maciejewski, et al.
Blood (2021) Vol. 138, Iss. 20, pp. 1928-1938
Open Access | Times Cited: 67
Management of Paroxysmal Nocturnal Haemoglobinuria: a personal view
Lucio Luzzatto, Giacomo Gianfaldoni, Rosario Notaro
British Journal of Haematology (2011) Vol. 153, Iss. 6, pp. 709-720
Closed Access | Times Cited: 92
Lucio Luzzatto, Giacomo Gianfaldoni, Rosario Notaro
British Journal of Haematology (2011) Vol. 153, Iss. 6, pp. 709-720
Closed Access | Times Cited: 92
Complement therapy in atypical haemolytic uraemic syndrome (aHUS)
Edwin K.S. Wong, Tim Goodship, David Kavanagh
Molecular Immunology (2013) Vol. 56, Iss. 3, pp. 199-212
Open Access | Times Cited: 84
Edwin K.S. Wong, Tim Goodship, David Kavanagh
Molecular Immunology (2013) Vol. 56, Iss. 3, pp. 199-212
Open Access | Times Cited: 84
Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria
Tommaso Rondelli, Antonio M. Risitano, Régis Peffault de Latour, et al.
Haematologica (2013) Vol. 99, Iss. 2, pp. 262-266
Open Access | Times Cited: 79
Tommaso Rondelli, Antonio M. Risitano, Régis Peffault de Latour, et al.
Haematologica (2013) Vol. 99, Iss. 2, pp. 262-266
Open Access | Times Cited: 79
How we(’ll) treat paroxysmal nocturnal haemoglobinuria: diving into the future
Antonio M. Risitano, Régis Peffault de Latour
British Journal of Haematology (2021) Vol. 196, Iss. 2, pp. 288-303
Open Access | Times Cited: 53
Antonio M. Risitano, Régis Peffault de Latour
British Journal of Haematology (2021) Vol. 196, Iss. 2, pp. 288-303
Open Access | Times Cited: 53
Advancing therapeutic complement inhibition in hematologic diseases: PNH and beyond
Eleni Gavriilaki, Régis Peffault de Latour, Antonio M. Risitano
Blood (2021) Vol. 139, Iss. 25, pp. 3571-3582
Open Access | Times Cited: 48
Eleni Gavriilaki, Régis Peffault de Latour, Antonio M. Risitano
Blood (2021) Vol. 139, Iss. 25, pp. 3571-3582
Open Access | Times Cited: 48
Paroxysmal nocturnal hemoglobinuria and other complement-mediated hematological disorders
Antonio M. Risitano
Immunobiology (2012) Vol. 217, Iss. 11, pp. 1080-1087
Closed Access | Times Cited: 74
Antonio M. Risitano
Immunobiology (2012) Vol. 217, Iss. 11, pp. 1080-1087
Closed Access | Times Cited: 74
Paroxysmal Nocturnal Hemoglobinuria and the Complement System: Recent Insights and Novel Anticomplement Strategies
Antonio M. Risitano
Advances in experimental medicine and biology (2012), pp. 155-172
Closed Access | Times Cited: 68
Antonio M. Risitano
Advances in experimental medicine and biology (2012), pp. 155-172
Closed Access | Times Cited: 68
Toward complement inhibition 2.0: Next generation anticomplement agents for paroxysmal nocturnal hemoglobinuria
Antonio M. Risitano, Serena Marotta
American Journal of Hematology (2018) Vol. 93, Iss. 4, pp. 564-577
Open Access | Times Cited: 52
Antonio M. Risitano, Serena Marotta
American Journal of Hematology (2018) Vol. 93, Iss. 4, pp. 564-577
Open Access | Times Cited: 52
Safety and efficacy of pegcetacoplan in paroxysmal nocturnal hemoglobinuria
Raymond Wong
Therapeutic Advances in Hematology (2022) Vol. 13
Open Access | Times Cited: 27
Raymond Wong
Therapeutic Advances in Hematology (2022) Vol. 13
Open Access | Times Cited: 27
The complement alternative pathway in paroxysmal nocturnal hemoglobinuria: From a pathogenic mechanism to a therapeutic target
Antonio M. Risitano, Camilla Frieri, Eleonora Urciuoli, et al.
Immunological Reviews (2022) Vol. 313, Iss. 1, pp. 262-278
Open Access | Times Cited: 26
Antonio M. Risitano, Camilla Frieri, Eleonora Urciuoli, et al.
Immunological Reviews (2022) Vol. 313, Iss. 1, pp. 262-278
Open Access | Times Cited: 26
Complement therapeutics in inflammatory diseases: promising drug candidates for C3‐targeted intervention
Dimitrios C. Mastellos, Daniel Ricklin, Evlambia Hajishengallis, et al.
Molecular Oral Microbiology (2015) Vol. 31, Iss. 1, pp. 3-17
Open Access | Times Cited: 44
Dimitrios C. Mastellos, Daniel Ricklin, Evlambia Hajishengallis, et al.
Molecular Oral Microbiology (2015) Vol. 31, Iss. 1, pp. 3-17
Open Access | Times Cited: 44
Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape
Dimitrios C. Mastellos, Daniel Ricklin, Despina Yancopoulou, et al.
Expert Review of Hematology (2014) Vol. 7, Iss. 5, pp. 583-598
Open Access | Times Cited: 43
Dimitrios C. Mastellos, Daniel Ricklin, Despina Yancopoulou, et al.
Expert Review of Hematology (2014) Vol. 7, Iss. 5, pp. 583-598
Open Access | Times Cited: 43
Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future
Antonio M. Risitano, Serena Marotta
Seminars in Immunology (2016) Vol. 28, Iss. 3, pp. 223-240
Closed Access | Times Cited: 40
Antonio M. Risitano, Serena Marotta
Seminars in Immunology (2016) Vol. 28, Iss. 3, pp. 223-240
Closed Access | Times Cited: 40
Tissue-targeted regulators of complement for amelioration of human disease: rationale and novel therapeutic strategies
Fei Liu, Stefan Wawersik, Stephen Tomlinson, et al.
The Journal of Immunology (2025)
Open Access
Fei Liu, Stefan Wawersik, Stephen Tomlinson, et al.
The Journal of Immunology (2025)
Open Access
Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes
Michela Sica, Tommaso Rondelli, Patrizia Ricci, et al.
Journal of Hematology & Oncology (2017) Vol. 10, Iss. 1
Open Access | Times Cited: 35
Michela Sica, Tommaso Rondelli, Patrizia Ricci, et al.
Journal of Hematology & Oncology (2017) Vol. 10, Iss. 1
Open Access | Times Cited: 35
